real-time news and commentary for investors
Monday, Aug 19
Dara BioSciences announces At-the-Market sales agreement
- DARA BioSciences (DARA) enters into an "At-the-Market" Sales Agreement with BTIG.
- Pursuant to the agreement the company may sell from time to time, up to $2.73M in aggregate offering price of its common stock through BTIG, acting as sales agent.
- The company intends to use the proceeds to fund expenses related to the commercialization of its complementary portfolio of oncology products, including expenses for the commercial activities related to Soltamox, Gelclair, and Bionect, as well as for other general corporate purposes.
- Shares -1.3% AH.